Overview

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

Status:
RECRUITING

Trial end date:
2027-07-10

Target enrollment:

Participant gender:

Summary

The objective is to evaluate whether the neoadjuvant combination of tislelizumab (a PD-1 inhibitor) with interleukin-2 (IL-2) chemotherapy can significantly increase the Objective Response Rate (ORR) and the Pathological Complete Response rate (pCR) in patients with locally advanced rectal cancer who have Microsatellite Stable/Proficient Mismatch Repair (MSS/pMMR) status.

Phase:

PHASE2

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Treatments:

Capecitabine
Interleukin-2
Oxaliplatin
Radiotherapy
tislelizumab